Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-01-24
2006-01-24
Nolan, Patrick J. (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
active
06989148
ABSTRACT:
The present invention provides a method of treating Type I diabetes by administration of an effective amount of a glucagon-like peptide 1 or an analogue of glucagon-like peptide 1 either alone or in conjunction with a regimen of insulin administration.
REFERENCES:
patent: 5118666 (1992-06-01), Habener
patent: 5120712 (1992-06-01), Habener
patent: 5234906 (1993-08-01), Young et al.
patent: 5424286 (1995-06-01), Eng
patent: 91883/82 (1983-06-01), None
patent: 40275/93 (1994-01-01), None
patent: 55016/94 (1994-10-01), None
patent: 0 044 168 (1985-05-01), None
patent: 0 708 179 (1996-08-01), None
patent: 0 869 135 (1998-10-01), None
patent: 94 09496.8 (1994-05-01), None
patent: WO 90/11296 (1990-10-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 93/18786 (1993-09-01), None
patent: WO 92/25579 (1993-12-01), None
illustrated Stedmans Medical Dictionary 24thEdition, Williams & Wilkins , pp. 34 & 60, 1988.
Gutniak et al. N.E.J.M. vol. 326: 1316-1322 ,1992, May 1992.
D'Alessio et al. J. Clin. Invest. vol. 93: 2263-2266, 1994, May, 1994.
Ngu et al. The Protein Folding Problem and Tertiary Structure Prediction, 1994, Mere et al., (ed), Birkhauser, Boston MA. , pages 433, 492-495, 1994.
Fehmann, et al., “Insulinotropic Hormone Glucagon-like Peptide-1(7-37) Stimulation of Proinsulin Gene Expression and Proinsulin Biosynthesis in Insulinoma Beta TC-1 Cells,”Endocrinology, 130(1):159-66 (1992).
Gromoda, et al., “Desensitization of Glucagon-like Peptide 1 Receptors in Insulin-secreting βTC3 Cells: Role of PKA-independent Mechanisms,”Brit. Jour. Phar., 118:769-75 (1996).
Gromoda, et al., “Cellular Regulation of Islet Hormone Secretion by the Incretin Hormone Glucagon-like Peptide 1,”Eur. J. Physiol., 435:583-94 (1998).
Jones, et al., “Effects of Fedotozine on Gastric Emptying and Upper Gastrointestinal Symptoms in Diabetic Gastroparesis,”Ailment. Pharmacol. Ther., 14:937-43 (2000).
Andrews, et al., “Isolation and structures of Glucagon and Glucagon-like peptide from catfish pancreas,”Journal of Biological Chemistry, 260(7):3910-3914 (1985).
Bell, et al., “Hamster preproglucagon contains the sequence of glucagon and two related peptides,”Nature, 302(21):716-718 (1983).
Chou, et al., “A Radioimmunoassay for LY315902, an Analog of Glucagon-Like Insulinotropic Peptide, and Its Application in the Study of Canine Pharmacokinetics,”J. Pharm. Sci., 86(7):768-773 (1997).
Creutzfeldt, “Entero-Insular Axis and Diabetes Mellitus,”Horm. Metab. Res. Suppl., 26:13-18 (1992).
Cryer, et al., “Hypoglycemia in IDDM,”Diabetes, 38:1193-9 (1989).
D'Alessio, et al., “Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal,”J. Clin. Invest., 93:2263-2266 (1994).
Donahue, et al., “Postchallenge Glucose Concentration and Coronary Heart Disease in Men of Japanese Ancestry,”Diabetes, 36:689-692 (1987).
Dupre, et al., “Insulinotropic Effect of Glucagon-Like Peptide I (7-36) Amide in C-Peptide-Positive Type I Diabetes Mellitus,” Abstract 221, Page B38,Clinical and Investigative Medicine(1994).
Egan, et al., “Glucagon-like Peptide-1 (7-36) Amide (GLP-1) Enhances Insulin-Stimulated Glucose Metabolism in 3T3-L1 Adipocytes: One of Several Potential Extrapancreatic Sites of GLP-1 Action,”Endocrinology, 135(5):2070-2075 (1994).
Ferrannini, et al., “The Disposal of an Oral Glucose Load in Healthy Subjects: A Quantitative Study,”Diabetes, 34:580-588 (1985).
Ferrannini, et al., “The Disposal of an Oral Glucose Load in Patients with Non-Insulin-Dependent Diabetes,”Metabolism, 37(1):79-85 (1988).
Fraser, et al., “Hyperglycaemia Slows Gastric Emptying in Type 1 (Insulin-Dependent) Diabetes Mellitus,”Diabetologia, 33:675-680 (1990).
Fuller, et al., “Coronary-Heart-Disease Risk and Impaired Glucose Tolerance,”The Lancet, 1373-1376 (1980).
Gerich, et al., “Prevention of Human Diabetic Ketoacidosis by Somatostatin,”New England J. Med., 292(19):985-999 (1975).
Ghiglione, et al., “How Glucagon-Like is Glucagon-Like peptide-1?”Diabetologia27:599-600 (1984).
Gromada, et al., “Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic β-Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling,”Diabetes, 47:57-65 (1998).
Gutniak, et al., “Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus,”New England Journal of Medicine, 326(20):1316-1322 (1992).
Gutniak, et al., “Glucagon-Like Insulinotropic Peptide 1 (7-36)—New Approach to Treating Diabetes?,”Diabetologia, (Published from the 26thAnnual Meeting of the European Association for the Study of Diabetes), 33(Supp.):A73 (1990).
Hargrove, et al., “Comparison of the Glucose Dependency of Glucagon-Like Peptide-1(7-37) and Glyburide In Vitro and In Vivo,”Metabolism, 45(3):404-409 (1996).
Hargrove, et al., “Glucose-Dependent Action of Glucagon-Like Peptide-1(7-37) In Vivo During Short- or Long-Term Administration,”Metabolism, 44(9):1231-1237.
Hendrick, et al., “Glucagon-like Peptide 1 (7-37) Blunts Postprandial Glycaemic Excursion in Rats with Mild Diabetes,”Diabetologia, 32(7):496A (1989) (Abstract).
Hendrick, et al., “Glucagon-like Peptide-1-(7-37) Suppresses Hyperglycemia in Rats,”Metabolism, 42(1):1-6 (1993).
Holst, “Glucagon Peptide 1: A Newly Discovered Gastrointestinal Hormone,”Gastroenterology, 107(6):1848-1855 (1994) (Abstract).
Horowitz, et al., “Disordered Gastric Motor Function in Diabetes Mellitus,”Diabetologia, 37:543-551 (1994).
Horowitz, et al., “Effects of Diabetes Mellitus on Gastrointestinal Motor Function,”Neuroscience Research Comm., 21(1):75-82 (1997).
Horowitz, et al., “Gastrointestinal Motor Function in Diabetes Mellitus: Relationship to Blood Glucose Concentration,”J. Gastro. Hep. 13(Supp.):S239-S245 (1998).
Horowitz, et al., “Gastric Emptying in Diabetes: An Overview,”Diabet. Med., 13(9 Supp. 5):S16-22 (Abstract) (1996).
Horowitz, et al., “Gastroparesis: Diagnosis and Management,”Scand. J. Gastroenterol. Suppl., 213:7-16 (Abstract) (1995).
Horowitz, et al., “Relationship Between Oesophaegeal Transit and Solid and Liquid Gastric Emptying in Diabetes Mellitus,”Eur. J. Nucl. Med., 18:229-234 (1991).
Horowitz, et al., “Relationship Between Oral Glucose Tolerance and Gastric Emptying in Normal Healthy Subjects,”Diabetologia, 36:857-862 (1993).
Hvidberg, et al., “Effect of Glucagon-like Peptide-1 (Proglucagon 78-107 Amide) on Hepatic Glucose Production in Healthy Man,”J. Metabolism, 43(1):104-108 (1994).
Jackson, et al., “A Comparison of the Relationships of the Glucose Tolerance Test and the Glycated Haemoglobin Assay with Diabetic Vascular Disease in the Community,”Diabetes Res. and Clin. Prac., 17:111-123 (1992).
Knudsen, et al., “Potent Derivatives of Glucagon-like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration,”J. Med. Chem., 43(9):1664-1669 (2000).
Kong, et al., “Natural History of Diabetic Gastroparesis,”Diabetes Care, 22(3):503-507 (1999).
Kreymann, et al., “Glucagon-like Peptide-1 7-36 Amide, A New Brain-Gut Hormone and Its Effect of Pancreatic Endocrine Function in Man,”Biomed. Res. 9(Supp. 3):207-211 (1988).
Kreymann, et al., “Glucagon-like Peptide-1 7-36: A Physiological Incretin in Man,”Lancet, 2:1300-1304 (1987).
Kumar, et al., “Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomye
Nolan Patrick J.
Sim & McBurney
LandOfFree
Treatment of diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528918